Progress in anti-invasion and anti-metastasis research and treatment (Review)

International Journal of Oncology

Volumn 9, Issue 5, 1996, Pages 1013-1028

  Jiang, Wen G ^a   Mansel, Robert E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

angiogenesis; cancer therapy; cell adhesion; extracellular matrix; invasion; metastasis

Indexed keywords

ANTIMETASTATIC AGENT; UNINDEXED DRUG;

CANCER; CANCER INVASION; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0029907651     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (291)

1. Hart IR, Goode NT and Wilson RE: Molecular aspects of the metastatic cascade. Biochim Biophys Acta 989: 65-84, 1989.
2. Liotta LA and Stracke ML: Tumor invasion and metastases: Biochemical mechanisms. Cancer Treat Res 40: 223-238, 1988.
3. Jiang WG, Puntis MCA and Hallett MB: The molecular and cellular basis of cancer invasion and metastasis and its implications for treatment. Br J Surg 81: 1576-1590, 1994.
4. Stetler-Stevenson WG, Liotta LA and Kleiner DE Jr: Role of matrix metalloproteinase in tumor invasion and metastasis. FASEB J 7: 1434-1441, 199.
5. Schmitt M and Graeff JH: Tumour associated proteases. Fibrinolysis 6: 3-26, 1992.
6. Brooks PC, Stromblad S, Sanders LC, Vonschalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85: 683-693, 1996.
7. Chintala SK, Sawaya R, Gokaslan ZL and Rao JS: Modulation of matrix metalloprotease-2 and invasion in human gliomacells by α3β1 integrin. Cancer Lett 103: 201-208, 1996.
8. Fife RS and Sledge GW: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast-carcinoma cells. J Lab Clin Med 125: 407-411, 1995.
9. Galardy RE, Grobelny D, Foellmer HG and Fernandez LA: Inhibition of angiogenesis by the matrix metalloprotease inhibitor n-[2R-2(hydroxamidocarbonymethyl)-4- methyl-pentanoyl)]-tryptophan methylamide. Cancer Res 54: 4715-4718, 1994.
10. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W and Brown PD: Control of lymphatic and hematogenous metastasis of a rat mammary-carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815-2822, 1996.
11. Sledge GW, Qulali M, Goulet R, Bone EA and Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast-cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995.
12. Tsuchida A, Ooishi H, Hanada K and Kajiyama G: Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic-cancer cell lines. FEBS Lett 383: 241-244, 1996.
13. Nakagawa T, Kubota T, Kabuto M and Kodera T: Captopril inhibits glioma cell invasion in vitro-involvement of matrix metalloproteinases. Anticancer Res 15: 1985-1989, 1995.
14. Fujii H, Nakajima M, Aoyagi T and Tsuruo T: Inhibition of tumor-cell invasion and matrix degradation by aminopeptidase inhibitors. Biol Pharmaceut Bull 19: 6-10, 1996.
15. Talmadge JE, Lenz BF, Pennington R, Long C, Philips H, Schneider M and Tribble H: Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 46: 4505-4510, 1986.
16. Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L and Shipp MA: Stromelysin-3 is overexpressed by stromal elements in primary non-small-cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 55: 4120-4126, 1995.
17. Hendrix MCJ, Wood WR, Seftor REB, Stetler-Stevenson WG, Bevacqua S, Liotta LA, Sobel ME, Raz A and Lotan R: Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 50: 4121-4130, 1990.
18. Stearns M, Wang M and Stearns ME: Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase-1 in primary human prostate tumor-cell lines. Oncol Res 7: 173-181, 1995.
19. Stearns ME, Wang M and Stearns M: IL-10 blocks collagen-IV invasion by invasion stimulating factor-activated PC-3 ML cells - up-regulation of TIMP-1 expression. Oncol Res 7: 157-163, 1995.
20. Kawada M and Umezawa K: Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analog inhibiting the urokinase-plasmin system. Biochem Biophys Res Commun 209: 25-30, 1995.
21. Hatai M, Hashi H, Kato I and Yaoi Y: Inhibition of cell adhesion by proteolytic fragments of type V collagen. Cell Structure Function 18: 53-60, 1993.
22. Woynarowska B, Wikiel H, Sharma M, Carpenter N, Fleet GW and Bernacki RJ: Inhibition of human ovarian carcinoma cell-and hexosaminidase-mediated degradation of extracellular matrix by sugar analogs. Anticancer Res 12: 161-166, 1992.
23. Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ and Littlefield BA: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53: 2553-2559, 1993.
24. Kobayashi H, Ohi H, Sugimura M, Fujii T, Terao T, Schmitt M, Goretzki L, Chuncholowski N, Janicke F and Graeff H: Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by aminoterminal fragment and subsequent effect on reconstructed basement membranes invasion. Br J Cancer 67: 537-544, 1993.
25. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA and Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025, 1993.
26. Popowicz P, Engel G, Marshall H and Linder S: Repression of stromelysin metalloprotease expression in rat fibrosarcoma cells by dimethylsulfoxide. Clin Exp Metastasis 11: 77-82, 1993.
27. Yohem KH, Clothier JL, Montague SL, Geary RJ, Winters AL III, Hendrix MJ and Welch DR: Inhibition of tumor cell invasion by verapamil. Pigm Cell Res 4: 225-233, 1991.
28. Isoe T, Naito M, Hirai R and Tsuruo T: Inhibition of ubiquitin-ATP-dependent proteolysis and ubiquitination by cisplatin. Anticancer Res 11: 1905-1909, 1991.
29. Kinder DH, Elstad CA, Meadows GG and Ames MM: Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Invasion Metastasis 12: 309-319, 1992.
30. Murata J, Saiki I, Makabe T, Tsuta Y, Tokura S and Azuma I: Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res 51: 22-26, 1991.
31. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EK, Medcalf RL, Testuz J and Sordat B: Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87: 6939-6943, 1990.
32. Quax PH, van Muijen GN, Weening-Verhoeff EJ, Lund LR, Dano K, Ruiter DJ and Verheijen JH: Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115: 191-199, 1991.
33. Rao JS, Baker JB, Morantz RA, Kimler B, Evans R and Festoff BW: Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. Cancer Res 50: 5039-5044, 1990.
34. Baker MS, Bleakley P, Woodrow GC and Doe WF: Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50: 4676-4684, 1990.
35. Stief TW, Radtke KP and Heimburger N: Inhibition of urokinase by protein C inhibitor (PCI). Evidence for identity of PCI and plasminogen activation inhibitor 3. Biol Chem Hoppe-Seyler 368: 1427-1433, 1987.
36. Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR, Murphy G and Reynolds JJ: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318: 66-69, 1985.
37. Declerck YA, Yean TD, Ratzkin BJ, Lu HS and Langley KE: Purification and characerization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J Biol Chem 264: 17445-17453, 1989.
38. DeClerck Y, Perez N, Shimada H, Boone TC, Langley KE and Taylor SE: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701-708, 1992.
39. DeClerck YA, Yean TD, Chan D, Shimada H and Langley KE: Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 51: 2151-2157, 1991.
40. Stetler-Stevenson WG, Krutzsch HG and Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989.
41. Nielsen KL and Sottrup-Jensen L: Evidence from sequence analysis that hen egg-white ovomacroglobulin (ovostatin) is devoid of an internal β-Cys-γ-Glu thiol ester. Biochim Biophys Acta 1162: 230-232, 1993.
42. Khokha R, Zimmer MJ, Graham CH, Lala PK and Waterhouse P: Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinases-1(TIMP-1) in B16F10 melanoma cells. J Natl Cancer Inst 84: 1017-1022, 1992.
43. Alverex OA, Carmichael DF and DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589-595, 1990.
44. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779, 1991.
45. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA and Stetler-Stevenson WG: TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576: 203-207, 1992.
46. Pavloff N, Staskus PW, Kishnani NS and Hawkes SP: A new inhibitor of metalloproteinases from chicken: ChIMP3, a third member of the TIMP family. J Biol Chem 267: 17321-17326, 1992.
47. Nelles JP and Schnebli HP: Are proteinase inhibitors potentially useful in tumor therapy? Invasion Metastasis 2: 113-124, 1982.
48. Uetsuji S, Yamamura M, Takai S, Hioki K and Yamamoto M: Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today 22: 439-442, 1992.
49. Rao JS, Kahler CB, Baker JB and Festoff BW: Protease nexin I, a serpin inhibits plasminogen-dependent degradation of muscle extracellular matrix. Muscle Nerve 12: 640-646, 1989.
50. Guttridge DC, Lau AL and Cunningham DD: Protease nexin-1, a thrombin inhibitor, is regulated by interleukin-1 and dexamethasone in normal human fibroblasts. J Biol Chem 268: 18966-18974, 1993.
51. Dabrowska M, Kemona H, Prokopowicz J, Kretowska J and Kiluk S: Serum antithrombin III and α-2-antiplasmin concentrations in patients with Hodgkin's disease in the course of chemotherapy. Neoplasma 38: 249-252, 1991.
52. Stenman UH, Koivunen E and Itkonen O: Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest 207: 5-9, 1991.
53. Kobayashi H, Gotoh J, Shinohara H, Moniwa N and Terao T: Inhibition of the metastasis of Lewis lung-carcinoma by antibody against urokinase-type plasminogen-activator in the experimental and spontaneous metastasis model. Thromb Haemost 71: 474-480, 1994.
54. Kobayashi H, Shinohara H, Fujie M, Gotoh J, Itoh M, Takeuchi K and Terao T: Inhibition of metastasis of Lewis lung-carcinoma by urinary trypsin-inhibitor in experimental and spontaneous metastasis models. Int J Cancer 63: 455-462, 1995.
55. Timar J, Diczhazi C, Bartha I, Pogany G, Paku S, Raso E, Tovari J, Ladanyi A, Lapis K, Kopper L and Jeney A: Modulation of heparan-sulfate chondroitin-sulfate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor-cells. Int J Cancer 62: 755-761, 1995.
56. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S and Delrosso M: Reversion of the invasive phenotype of transformed human fibroblasts by and messenger oligonucleotide inhibition of urokinase receptor gene-expression. Cancer Res 55: 90-95, 1995.
57. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T and Seiki M: Inhibition of metastasis in human gastric-cancer cells transfected with tissue inhibitor of metalloproteinase-1 gene in nude mice. Cancer 77: 1676-1680, 1996.
58. Imren S, Kohn Db, Shimada H, Blavier L and DeClerck YA: Overexpression of tissue inhibitor of metalloproteinases- 2 by retroviral-mediated gene transfer in vivo inhibits tumor-growth and invasion. Cancer Res 56: 2891-2895, 1996.
59. Fazioli F and Blasi F: Urokinase-type plasminogen activator and its receptor - new targets for antimetastatic therapy. Trend Pharmacol Sci 15: 25-29, 1994.
60. Thompson S, Wong E, Cantwell BM and Turner GA: Serum α1 proteinase inhibitor with abnormal properties in ovarian cancer. Clin Chim Acta 193: 13-25, 1990.
61. Knutson JR, Iida J, Fields GB and McCarthy JB: CD44/ chondroitin sulfate proteoglycan and α2β1 integrin mediate human-melanoma cell-migration on type-IV collagen and invasion of basement-membranes. Mol Biol Cell 7: 383-396, 1996.
62. Elliott BE, Ekblom P, Pross H, Niemann A and Rubin K: Anti-β1-integrin IgG inhibits pulmonary macrometastasis and the size of micrometastases from a murine mammary carcinoma. Cell Adhesion Commun 1: 319-332, 1994.
63. Newton SA, Reeves EJ, Gralnick H, Mohla S, Yamada KM, Olden K and Akiyama SK: Inhibition of experimental metastasis of human breast-carcinoma cells in athymic nude-mice by anti-α5β1 fibronectin receptor integrin antibodies. Int J Oncol 6: 1063-1070, 1995.
64. Pieschbacher MD and Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309: 30-33, 1984.
65. Yamada KM and Kennedy DW: Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J Cell Biol 99: 29-36, 1984.
66. D'Souza SE, Hinsberg MH and Plow EF: Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. TIBS 16: 246-250, 1991.
67. Gehlsen KR, Argraves WS, Pierschbacher MD and Ruoslahti E: Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 106: 925-930, 1988.
68. Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E and Liotta LA: Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 110: 1427-1438, 1990.
69. Isoai A, Ueno Y, Goga-Hama Y, Goto H and Kumagai H: A novel Arg-Gly-Asp containing peptide specific for platelet aggregation and its effect on tumor metastasis. Cancer Lett 65: 259-264, 1992.
70. Soszka T, Knudsen KA, Beviglia L, Rossi C, Poggi A and Niewiarowski S: Inhibition of murine melanoma cell matrix adhesion and experimental metastasis by albolabrin, an RGD-containing peptide isolated from the venom of Trimeresurus albolabris. Exp Cell Res 196: 6-12, 1991.
71. Saiki I, Murata J, Matsuno K, Ogawa R, Nishi N, Tokura S and Azuma I: Anti-metastatic and anti-invasive effects of polymeric Arg-Gly-Asp (RGD) peptide poly(RGD), and its analogues. Jpn J Cancer Res 81: 660-667, 1990.
72. Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y, Kato I and Azuma I: Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res 84: 326-335, 1993.
73. Saiki I, Yoneda J, Igarashi Y, Aoki M, Kusunose N, Ono K and Azuma I: Antimetastatic activity of polymeric RGDT peptides conjugated with poly(ethylene glycol). Jpn J Cancer Res 84: 558-565, 1993.
74. Chambers AF, Hota C and Prince CW: Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin. Cancer Res 53: 701-706, 1993.
75. Murthy MS, Scanlon EF, Silverman RH, Goodheart CR, Goldschmidt RA and Jelachich ML: The role of fibronectin in tumor implantation at surgical sites. Clin Exp Metastasis 11: 159-173, 1993.
76. Greenspoon N, Hershkoviz R, Alon R, Varon D, Shenkman B, Marx G, Federman S, Kapustina G and Lider O: Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence. Biochemistry 32: 1001-1008, 1993.
77. Ostheimer GJ, Starkey JR, Lambert CG, Helgerson SL and Dratz EA: NMR constrained solution structure for laminin peptide 11. J Biol Chem 267: 25120-25128, 1992.
78. Castronovo V, Taraboletti G and Sobel ME: Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. Cancer Res 51: 5672-5678, 1991.
79. Blood CH and Zetter BR: Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit α 6. Cancer Res 53: 2661-2666, 1993.
80. Sipes JM, Guo N, Negre E, Vogel T, Krutzsch HC and Roberts DD: Inhibition of fibronectin binding and fibronectin mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. J Cell Biol 121: 469-477, 1993.
81. Boukerche H, Berthiervergnes O, Tabone E, Bailly M, Dore JF and Mcgregor JL: Thrombospondin modulates melanoma platelet interactions and melanoma tumor-cell growth in vivo. Br J Cancer 71: 108-116, 1995.
82. Folkman J, Weisz PB, Jouille MM, Li WW and Ewing WR: Control angiogenesis with synthetic heparin substitute. Science 243: 1490-1493, 1989.
83. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
84. Brem H, Ingber D, Blood CH, Bradley D, Urioste S and Folkman J: Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 42: 439-441, 1991.
85. Folkman J: The influence of angiogenesis research on management of patients with breast-cancer. Breast Cancer Res Treat 36: 109-118, 1995.
86. Gagliardi AR, Hennig B and Collins DC: Antiestrogens inhibit endothelial-cell growth stimulated by angiogenic-growth factors. Anticancer Res 16: 1101-1106, 1996.
87. Norrby K and Ostergaard P: Basic-fibroblast-growth factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcircul 16: 8-15, 1996.
88. Derbyshire EJ, Comin GA, Yang YC, Overholser J, Watkins L and Thorpe PE: Antitumor and anti-angiogenic effects in mice of heparin conjugated to angioslatic steroids. Int J Cancer 63: 694-701, 1995.
89. Thorpe PE, Derbyshire EJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang YC and Rao-Bette M: Heparin steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res 53: 3000-3007, 1993.
90. Shklar G and Schwartz JL: Vitamin-E inhibits experimental carcinogenesis and tumor angiogenesis. Eur J Cancer 32B: 114-119, 1996.
91. Majewski S, Marczak M, Szmurlo A, Jablonska S and Bollag W: Interleukin-12 inhibits angiogenesis induced by human tumor cell-lines in vivo. J Invest Dermatol 106: 1114-1118, 1996.
92. Voest EE, Kenyon BB, Oreilly MS, Truitt G, Damato RJ and Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
93. Nguyen NM, Lehr JE and Pienta KJ: Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor-growth in vivo. Anticancer Res 13: 2143-2147, 1993.
94. Ono M, Kawahara N, Goto D, Wakabayashi Y, Ushiro S, Yoshida S, Izumi H, Kuwano M and Sato Y: Inhibition of tumor-growth and neovascularization by an antigastric ulcer agent, irsogladine. Cancer Res 56: 1512-1516, 1996.
95. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N and Fidler IJ: Interferon-α and interferon-β down-regulate the expression of basic fibroblast growth-factor in human carcinomas. Proc Natl Acad Sci USA 92: 4562-4566, 1995.
96. Singh RK, Bucana CD, Llansa N, Sanchez R and Fidler IJ: Cell density-dependent modulation of basic fibroblast growth-factor expression by human interferon-β. Int J Oncol 8: 649-656, 1996.
97. Majewski S, Szmurlo A, Marczak M, Jablonska S and Bollag W: Synergistic effect of retinoids and interferon-α on tumor-induced angiogenesis - anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 57: 81-85, 1994.
98. Majewski S, Marczak M, Szmurlo A, Jablonska S and Bollag W: Retinoids, interferon-α, 1,25-dihydroxyvitamin D-3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor-cell lines - RAR-α mediates the anti-angiogenic effect of retinoids. Cancer Lett 89: 117-124, 1995.
99. Lingen MW, Polverini PJ and Bouck NP: Inhibition of squamous-cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial-cells. Lab Invest 74: 476-483, 1996.
100. Ito K, Abe T, Tomita M, Motimoto A, Kohno K, Mori T, Ono M, Sugenoya A, Nishihira T and Kuwano M: Anti angiogenic activity of arachidonic acid metabolism inhibitor in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice. Int J Cancer 55: 660-666, 1993.
101. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamuru T, Brem H and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557, 1990.
102. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP and Brien SE: Inhibition of angiogenesis and tumor growth in the brain. Am J Pathol 137: 1121-1142, 1990.
103. Sharpe RJ, Byers HR, Scott CF, Bauer SI and Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82: 848-853, 1991.
104. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF and Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247: 77-79, 1990.
105. Kolber DL, Knisely TL and Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 87: 304-309, 1995.
106. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B and Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56: 569-573, 1996.
107. Cao YH, Chen C, Weatherbee JA, Tsang M and Folkman J: GRO-β, GRO-α -C-X-C-chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis-lung carcinoma in mice. J Exp Med 182: 2069-2077, 1995.
108. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes up-regulate VEGF/VPF expression - implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
109. Pipilisynetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, Karakiulakis G and Maragoudakis ME: Inhibition of angiogenesis, tumor-growth and metastasis by the no-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 116: 18291834, 1995.
110. Iigo M, Shimamura M, Sagawa K and Tsuda H: Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon-carcinoma-26. Jpn J Cancer Res 86: 867-872, 1995.
111. Borgstrom P, Filho IPT and Hartleyasp B: Inhibition of angiogenesis and metastases of the Lewis lung-cell carcinoma by the quinoline-3-carboxamide, linomide(r). Anticancer Res 15: 719-728, 1995.
112. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833-1837, 1993.
113. Vukanovic J and Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499-1504, 1995.
114. Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N and Grandi M: Antitumor-activity of FCE-26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol 36: 217-222, 1995.
115. Coomber BL: Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 58: 199-207, 1995.
116. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K and Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial-cell binding of basic fibroblast growth-factor, migration, proliferation, and induction of urokinase-type plasminogen-activator. Cancer Res 54: 2654-2660, 1994.
117. Harris AL, Zhang HT, Moghaddam A, Fox S, Scott P, Pattison A, Gatter K, Stratford I and Bicknell R: Breast cancer angiogenesis - new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targetins. Breast Cancer Res Treat 38: 97-108, 1996.
118. Candal FJ, Bosse DC, Vogler WR and Ades EW: Inhibition of induced angiogenesis in a human microvascular endothelial-cell line by ET-18-OCH3. Cancer Chemother Pharmacol 34: 175-178, 1994.
119. Stravoravdi P, Toliou T and Polyzonis M: Protamine sulfate - a new chemopreventive role for an anti-angiogenic substance. Cancer J 7: 81-84, 1994.
120. Fotsis T, Zhang YM, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L: The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor-growth. Nature 368: 237-239, 1994.
121. Fujimoto J, Fujita H, Hosoda S, Okada H and Tanaka NG: Effect of medroxyprogesterone acetate on secondary spreading of endometrial cancer. Invasion Metastasis 9: 209-215, 1989.
122. Fujimoto J, Hosoda S, Fujita H and Okada H: Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors. Invasion Metastasis 9: 269-277, 1989.
123. Jikihara H, Terada N, Yamamoto R, Nishikawa Y, Tanizawa O, Matsumoto K and Terakawa N: Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol 167: 207-211, 1992.
124. Yamamoto T, Terada N, Nishizawa Y and Petrow V: Angiostatic activities of medroxyprogesterone acetate and its analogs. Int J Cancer 56: 393-399, 1994.
125. Bastaki M, Missirlis E, Klouras N, Karakiulakis G and Maragoudakis ME: Suppression of angiogenesis by the antitumor agent titanocene dichloride. Eur J Pharmacol 251: 263-269, 1994.
126. Majewski S, Szmurlo A, Marczak M, Jablonska S and Bollag W: Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin-D3 and their combination. Cancer Lett 75: 35-39, 1993.
127. Teicher BA, Sotomayor EA and Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992.
128. Tamargo RJ, Bok RA and Brem H: Anciogenesis inhibition by minocycline. Cancer Res 51: 672-675, 1991.
129. Murata J, Saiki I, Matsuno K, Tokura S and Azuma I: Inhibition of tumor cell arrest in lungs by antimetastatic chitin heparinoid. Jpn J Cancer Res 81: 506-513, 1990.
130. Billington DC: Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Design Discov 8: 3-35, 1991.
131. Bagavandoss P, Kaytes P, Vogeli G, Wells PA and Wilks JW: Recombinant truncated thrombospondin-1 monomer modulates endothelial cell plasminogen activator inhibitor 1 accumulation and proliferation in vitro. Biochem Biophys Res Commun 192: 325-332, 1993.
132. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
133. Sakamoto N, Iwahana M, Tanaka NG and Osada Y: Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 51: 903-906, 1991.
134. Saiki I, Sato K, Yoo YC, Murata J, Yoneda J, Kiso M, Hasegawa A and Azuma I: Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-γ followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer 51: 641-645, 1992.
135. Eijan AM, Davel L, Oisgold-Daga S and de Lustig ES: Modulation of tumor-induced angiogenesis by proteins of extracellular matrix. Mol Biother 3: 38-40, 1991.
136. Oreilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao YH, Sage EH and Folkman J: Angiostatin - a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
137. Missirlis E, Karakiulakis G and Maragoudakis ME: Antitumor effect of GPA1734 in rat Walker 256 carcinoma. Invest New Drugs 8: 145-147, 1990.
138. Maragoudakis ME, Missirlis E, Karakiulakis GD, Sarmonica M, Bastakis M and Tsopanoglou N: Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int 43: 147-150, 1993.
139. Kusaka M, Sudo K, Fujita T, Mauri S, Itoh F, Ingber D and Folkman J: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174: 1070-1076, 1992.
140. Yanase T, Tamura M, Fujita K, Kodama S and Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566-2570, 1993.
141. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa Y and Toguchi H: Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exp Ther 264: 469-474, 1993.
142. Schoof DD, Obando JA, Cusack JC, Goedegebuure PS, Brem H and Eberlein TJ: The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumour growth in vitro. Int J Cancer 55: 630-635, 1993.
143. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K and Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor-growth of hormone-independent human breast and prostate carcinoma cell-lines. Cancer Res 53: 5233-5236, 1993.
144. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K and Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol. Cancer Res 53: 4262-4267, 1993.
145. Fujioka T, Hasegawa M, Ogiu K, Matsushita Y, Sato M and Kubo T: Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal-cell carcinoma. J Urol 155: 1775-1778, 1996.
146. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP470, in xenotransplanted human colorectal-cancer with high metastatic potential. Cancer 77: 1736-1740, 1996.
147. Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Higashida T, Koyama H, Suganuma Y, Miyata K, Takeuchi K and Takahashi T: Intraartcrial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br J Cancer 72: 650-653, 1995.
148. Kitamura M, Arai K, Iwasaki Y and Toi M: Antitumor effect of the angiogenesis inhibitor TNP-470 and its combination effect with 5-FU and PSK in colon-26 tumors. Oncol Rep 3: 151-153, 1996.
149. Parangi S, Oreilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J and Hanahan D: Antiangiogcnic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93: 2002-2007, 1996.
150. Yano T, Tanase M, Watanabe A, Sawada H, Yamada Y, Shino Y, Nakano H and Ohnishi T: Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude-mice. Anticancer Res 15: 1355-1358, 1995.
151. Matsuoka S, Uchino J, Une Y, Ishimura H, Tsuchimoto S and Kamiyama T: Effects of TNP-470 (AGM1470) on tumor-growth, angiogenesis and serum copper levels in liver-cancer bearing rats. Oncol Rep 2: 583-589, 1995.
152. Teicher BA, Holden SA, Ara G, Korbut T and Menon K: Comparison of several antiangiogenic regimes alone and with cytotoxic therapies in the Lewis lung-carcinoma. Cancer Chemother Pharmacol 38: 169-177, 1996.
153. Ito Y, Iwamoto Y, Oshima N and Sugioka Y: Quantitative-evaluation of the effects of an angiogenesis inhibitor, TNP-470, by an in vivo tumor angiogenesis assay using basement-membrane extracts. Cancer J 9: 95-100, 1996.
154. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y and Goff D: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary-carcinoma. Breast Cancer Res Treat 36: 227-236, 1995.
155. Kato T, Sate K, Kakinuma H and Matsuda Y: Enhanced suppression of tumor-growth by combination of angiogenesis inhibitor o-(chloroacetyl carbarnoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147, 1994.
156. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small-cell lung cancer in SCID mice. J Clin Invest 97: 2792-2802, 1996.
157. Asano M, Yukita A, Matsumoto T, Kondo S and Suzuki H: Inhibition of tumor-growth and metastasis by an immunoneutralizing monoclonal-antibody to human vascular endothelial growth-factor vascular permeability factor. Cancer Res 55: 5296-5301, 1995.
158. Olson TA, Mohanraj D and Ramakrishnan S: In vivo neutralization of vascular endothelial growth-factor (VEGF) vascular-permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor-growth. Int J Oncol 8: 505-511, 1996.
159. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA: Anti-integrin αvβ3 blocks human breast-cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822, 1995.
160. Olson KA, Fett JW, French TC, Key ME and Vallee BL: Angiogenin antagonists prevent tumor-growth in vivo. Proc Natl Acad Sci USA 92: 442-446, 1995.
161. Ramakrishnan S, Olson TA, Bautch VL and Mohanraj D: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/FLK-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330, 1996.
162. Zhu D, Cheng CF and Pauli BU: Blocking of lung endothelial cell adhesion molecule-1 (Lu-ECAM-I) inhibits murine melanoma lung metastasis. J Clin Invest 89: 1718-1724, 1992.
163. Elsabban ME and Pauli BU: Adhesion-mediated gap junctional communication between lung-metastatic cancer cells and endothelium. Invasion Metastasis 14: 1-6, 1994.
164. Tozawa K, Sakurada S, Kohri K and Okamoto T: Effects of antinuclear factor-χ-β reagents in blocking adhesion of human cancer-cells to vascular endothelial cells. Cancer Res 55: 4162-4167, 1995.
165. Masamune A, Hakomori S and Igarashi Y: N,N,N-trimethylsphingosine inhibits interleukin-1β-induced NF χ-β activation and consequent E-selectin expression in human umbilical vein endothelial-cells. FEBS Lett 367: 205-209, 1995.
166. Bliss RD, Kirby JA, Browell DA and Lennard TWJ: The role of β1-integrins in adhesion of 2 breast-carcinoma cell-lines to a model endothelium. Clin Exp Metastasis 13: 173-183, 1995.
167. Schiffmann E: Motility as a principal requirement for metastasis. Cancer Invest 8: 673-674, 1990.
168. Jiang WG, Hallett MB and Puntis MCA: Motility factors in cancer invasion and metastasis. Surg Res Commun 16: 219-237, 1994.
169. Isoai A, Giga-hama Y, Shinkai K, Mukai M, Akedo H and Kumagai H: Purification and characterization of tumor invasion-inhibiting factors. Jpn J Cancer Res 81: 909-914, 1990.
170. Isoai A, Giga-Hama Y, Shinkai K, Mukai M, Akedo H and Kumagai H: Tumor invasion-inhibiting factor 2: Primary structure and inhibitory effect on invasion in vitro and pulmonary metastasis of tumor cells. Cancer Res 52: 1422-1426, 1992.
171. Isoai A, Goto-Tsukamoto H, Murakami K, Akedo H and Kumagai H: A potent anti-metastatic activity of tumor invasion - inhibiting factor 2 and albumin conjugate. Biochem Biophys Res Commun 192: 7-14, 1993.
172. Isoai A, Goto-Tsukamoto H, Yamori T, et al: Inhibitory effects of tumor invasion inhibiting factor 2 and its conjugate on disseminating tumor cells. Cancer Res 54: 1264-1270, 1994.
173. Jiang WG, Hiscox S, Singhrao SK, et al: Inhibition of motility and invasion by invasion inhibiting factor 2 (IIF2) on human colon cancer cells. Surg Res Commun 17: 67-78, 1995.
174. Kurebayashi J, Kurosumi M, Isoai A, Dickson RB and Sonoo H: Invasion-inhibiting factor 2-albumin conjugate inhibits invasion and spontaneous metastasis of MKL-4 human breast-cancer cells transplanted into female nude mice. Clin Exp Metastasis 14: 87-94, 1996.
175. Han ZG, Jiang WG, Hiscox S, Hallett MB, Isoai A and Mansel RE: Inhibition of motility and invasion of human lung cancer cells by invasion inhibiting factor 2. Surg Oncol 5: 77-84, 1996.
176. Jiang WG, Hiscox S, Isoai A, Puntis MCA, Hallett MB and Mansel RE: Inhibition of motility of breast cancer cells by invasion inhibiting factor 2. Breast Cancer Res Treat 37: 83, 1996.
177. Miyake M, Koyama M, Seno M and Ikeyama S: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 174: 1347-1354, 1991.
178. Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M: Suppresion of cell motility and metastasis by transfection with human motility-related protein (MRP 1/CD9) DNA. J Exp Med 177: 1231-1237, 1993.
179. Chan AML, Rubin SJ, Bottaro DP, Hirschfield DW, Chedid M and Aaronson SA: Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 254: 1382-1385, 1991.
180. Lokker NA and Godowski PJ: Generation and characterization of a competitive antagonist of human hepatocyte growth factor. J Biol Chem 268: 17145-17150, 1993.
181. Jeon H, Niimi T, Taniguchi Y, Miki K and Kitagawa Y: Regulated expression of an osteonectin variant in bovine aortic endothelial-cells. Biosci Biotechnol Biochem 58: 1889-1891, 1994.
182. Cioce V, Csaky KG, Chan AML, Bottaro DP, Taylor WG, Jensen R, Aaronson SA and Rubin JS: Hepatocyte growth factor (HGF)/NK1 is a naturally-occurring HGF/scatter factor variant with partial agonist-antagonist activity. J Biol Chem 271: 13110-13115, 1996.
183. Mueller BM, Romerdahl CA, Trent JM and Reisfeld RA: Suppression of spontaneous melanoma metastasis in SCID mice with an antibody to the epidermal growth factor receptor. Cancer Res 51: 2193-2198, 1991.
184. Miyake M and Hakomori S: A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibits cell motility and tumour cells metastasis. Biochemistry 30: 3328-3334, 1991.
185. Fujita S, Suzuki H, Kinoshita M and Hirohashi S: Inhibition of cell attachment, invasion and metastasis of human carcinoma cells by anti-integrin β1 subunit antibody. Jpn J Cancer Res 83: 1317-1326, 1992.
186. Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen WT and Akiyama SK: Monoclonal antibody and synthetic peptide inhibitors of human tumour cell migration. Cancer Res 50: 4485-4496, 1990.
187. Stracke ML, Soroush M, Liotta LA and Schiffmann E: Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int 43: 151-157, 1993.
188. Slichenmyer WJ and Von Hoff DD: New natural products in cancer chemotherapy. J Clin Pharmacol 30: 770-788, 1990.
189. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cell. Proc Natl Acad Sci USA 77: 1651-1655, 1980.
190. Nicolaou KC, Yang Z, Liu JJ, et al: Total synthesis of taxol. Nature 367: 630-634, 1994.
191. Ueda M, Fujii H, Yoshizawa K, Abe F and Ueki M: Effects of sex steroids and growth-factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 87: 524-533, 1996.
192. Leone A, Platow U, Vanhoutte K and Steeg PS: Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line - effects on tumor metastatic potential, colonization and enzymatic-activity. Oncogene 8: 2325-2333, 1993.
193. Kantor JD, McCormick B, Steeg PS and Zetter BR: Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res 53: 1971-1973, 1993.
194. Collins JF, Herman P, Schuch C and Bagby GC Jr: c-myc antisense oligonucleotides inhibit the colony forming capacity of colo 320 colonic carcinoma cells. J Clin Invest 89: 1523-1527, 1992.
195. Kemler R: From cadherins to catenins. TIG 9: 317-321, 1993.
196. Jiang WG: E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg 83: 437-446, 1996.
197. Takeichi M: Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5: 806-811, 1993.
198. Mareel M, Berx G, Vanroy F and Bracke M: Cadherin/catenin complex - a target for antiinvasive therapy. J Cell Biochem 61: 524-530, 1996.
199. Hillman GG, Younes E, Visscher D, Ali E, Lam JS, Montecillo E, Pontes JE, Haas GP and Puri RK: Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal-cell carcinoma model. Cell Immunol 160: 257-263, 1995.
200. Jiang WG and Puntis MCA: Monocyte production of Interleukin-12 in patients with obstructive jaundice. HPB Surg 9: 219-221, 1996.
201. Chen HY, Wu SL, Yeh MY, Chen CF, Mikami Y and Wu JS: Antimetastatic activity induced by Clostridium butyricum and characterization of effector cells. Anticancer Res 13: 107-111, 1993.
202. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin-12 against murine tumor. J Exp Med 178: 1223-1230, 1993.
203. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA and Lotze MT: Cancer-immunotherapy of established tumors with IL-12 - effective delivery by genetically-engineered fibroblasts. J Immunol 155: 1393-1403, 1995.
204. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD and Lotze MT: Effective eradication of established murine tumors with IL-12 gene-therapy using a polycistronic retroviral vector. J Immunol 154: 6466-6474, 1995.
205. Tahara H and Lotze MT: Antitumor effects of interleukin-12 (IL-12) - applications for the immunotherapy and gene-therapy of cancer. Gene Ther 2: 96-106, 1995.
206. Hall SS: Immune therapies - IL-12 holds promise against cancer, glimmer of AIDS hope. Science 263: 1685-1686, 1994.
207. Hiscox S, Puntis MCA, Hallett MB and Jiang WG: Inhibition of motility and invasion of human colon cancer cells by interleukin-12. Clin Exp Metastasis 13: 396-404, 1995.
208. Zeh HJ, Hurd S, Storkus WJ and Lotze MT: Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors - implications for the immunotherapy of cancer. J Immunother 14: 155-161, 1993.
209. Horvatharcidiacono JA, Mostowski HS and Bloom ET: IL-12 administered in vivo to young and aged mice discrepancy between the effects on tumor-growth in vivo and cytotoxic T-lymphocyte generation ex-vivo dependence on IFN. Int J Immunol 8: 661-673, 1996.
210. Heuff G, van der Ende MB, Boutkan H, Prevoo W, Bayon LG, Fleuren GJ, Beelen HJ, Meijer S and Dijkstra CD: Macrophage population in different stages of induced hepatic metastasis in rats: an immunohistochemical analysis. Scand J Immunol 38: 1016, 1993.
211. Bucana CD, Fabra A, Sanchez R and Fidler IJ: Different patterns of macrophage infiltration into allogeneic murine and xenogeneic human neoplasms growing in nude mice. Am J Pathol 141: 1225-1236, 1992.
212. Jiang WG, Hiscox S, Hallett MB, Mansel RE and Puntis MCA: Regulation of motility and invasion of cancer cells by human monocytes. Anticancer Res 15: 1303-1310, 1995.
213. Kohn AE, Polverinin PJ, Gimbrone MA and Unanue ER: Induction of neovascularization by activated human monocytes. J Leuk Biol 39: 804-806, 1986.
214. Van Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher IG, Cavers D, Coy P and Brigden ML: Macrophage-tumor cell associations: a factor in metastasis of breast cancer? J Leuk Biol 54: 360-362, 1993.
215. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T and Blankenstein T: Interleukin-10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 53: 4134-4137, 1993.
216. Kundu N, Beaty TL, Jackson MJ and Fulton AM: Anti-metastatic and antitumor activities of interleukin-10 in a murine model of breast cancer. J Natl Cancer Inst 88: 536-541, 1996.
217. Powrie F, Menon S and Coffman RL: Interleukin-1 and interleukin-10 synergize to inhibit cell mediated immunity in vivo. Eur J Immunol 23: 3043-3049, 1993.
218. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G and Angel JB: A randomized controlled trial of IL-10 in humans. J Immunol 154: 5492-5499, 1995.
219. Hoefer M and Anderer FA: Anti-(transforming growth-factor-β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 41: 302-308, 1995.
220. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA and Mueller BM: Therapeutic potential of chimeric and murine anti-(epidermal growth-factor receptor) antibodies in a metastasis model for human-melanoma. Cancer Immunol Immunother 37: 343-349, 1993.
221. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L: Phase-II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal-antibody in patients with HER2/neu-overexpressing metastatic breast. J Clin Oncol 14: 737-744, 1996.
222. Hung MC, Matin A, Zhang YJ, Xing XM, Sorgi F, Huang L and Yu DH: HER-2 neu-targeting gene-therapy. Gene 159: 65-71, 1995.
223. Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, Trizio D and Segatto O: Expression of gp185(her2) in human cutaneous melanoma - implications for experimental immunotherapeutics. Int J Cancer 56: 341-346, 1994.
224. Weiner LM, Clark JI, Davey M, Li WS, Depalazzo IG, Ring DB and Alpaugh RK: Phase-I trial of 2B1, a bispecific monoclonal-antibody targeting c-erbβ-2 and Fc-γ-RIII. Cancer Res 55: 4586-4593, 1995.
225. Tajima H, Matsumoto K and Nakamura T: Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 291: 229-232, 1991.
226. Shiota G, Rhoads DB, Wang TC, Nakamura T and Schmidt E: Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 89: 373-377, 1992.
227. Shiota G, Kawasaki H, Nakamura T and Schmidt EV: Inhibitory effect of hepatocyte growth-factor against FAO hepatocellular-carcinoma cells may be associated with changes of intracellular signaling pathways mediated by protein-kinase-C. Res Commun Mol Pathol Pharmacol 85: 271-278, 1994.
228. Shiota G, Kawasaki H, Nakamura T and Schmidt EV: Inhibitory effect of hepatocyte growth-factor on metastasis of hepatocellular-carcinoma in transgenic mice. Res Commun Mol Pathol Pharmacol 91: 33-39, 1996.
229. Kato N, Nawa A, Tamakoshi K, Kikkawa F, Suganuma N, Okamoto T, Goto S, Tomoda Y, Hamaguchi M and Nakajima M: Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-β. Am J Obstet Gynecol 172: 601-616, 1995.
230. Takeda S, Horrobin DF, Manku M, Sim PG, Ells G and Simmons V: Lipid peroxidation in human breast cancer cells in response to γ-linolenic acid and iron. Anticancer Res 12: 329-333, 1992.
231. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Scott C and Puntis MCA: Inhibition of invasion and motility of human colon cancer cells by γ linolenic acid. Br J Cancer 71: 744-752, 1995.
232. Begin ME, Ells G, Das UN and Horrobin DF: Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 77: 1053-1062, 1986.
233. Begin ME, Ells G, Das UN and Horrobin DF: Polyunsaturated fatty acids induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80: 188-194, 1988.
234. Horrobin DF: Essential fatty acids, lipid peroxidation, and cancer. In: Omega-6 Essential Fatty Acids. Horrobin DF (ed). Wiley-Liss, New York, pp351-378, 1990.
235. Botha JH, Robinson KM, Ramchurren N and Norman RJ: The role of prostaglandins in the inhibition of cultured carcinoma cell growth produced by gamma linolenic acid. Prostagland Leuk Essent Fatty Acid 35: 119-123, 1989.
236. Hussey HJ and Tisdale MJ: Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 70: 6-10, 1994.
237. Honn KV, Nelson KK, Renaud C, Bazaz R, Diglio CA and Timar J: Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins 44: 413-429, 1992.
238. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MCA: Regulation of the expression of E-cadherin on human cancer cells by γ linolenic acid. Cancer Res 55: 5043-5048, 1995.
239. Jiang WG, Hiscox S, Puntis MCA, Hallett MB, Horrobin DF, Bryce R and Mansel RE: γ linolenic acid (GLA) inhibits tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and tumour cell matrix interaction. Int J Oncol 8: 583-587, 1996.
240. Jiang WG, Hiscox S, Hallett MB, Bryce R, Horrobin DF, Mansel RE and Puntis MCA: Inhibition of membrane ruffling and ezrin translocation by γ linolenic acid. Int J Oncol 9: 279-284, 1996.
241. Jiang WG, Bryce RP, Horrobin DF and Mansel RE: γ linolenic acid regulates gap junction communications in endothelial cells and their interaction with tumour cells. Prostagland Leuk Essent Fatty Acid (In press).
242. Fearon KCH, Falconer JS, Ross JA, Carter DC, Hunter JO, Reynolds PD and Tuffnell Q: An open label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res 16: 867-874, 1996.
243. Liu B, Timar J, Howlett J, Diglio CA and Honn KV: Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumour cells to endothelium via regulation of protein kinase C. Cell Regulation 2: 1045-1055, 1992.
244. Liu B, Renaud C, Nelson KK, Chen YQ, Bazaz R, Kowynia J, Timar J, Diglio CA and Honn KV: Protein-kinase C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization. Int J Cancer 52: 147-152, 1992.
245. Schwartz GK, Jiang J, Kelsen D and Albino AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85: 402-407, 1993.
246. Bouillon M and Audette M: Transduction of retinoic acid and γ interferon signal for intercellular adhesion molecule-1 expression on human tumor cell lines. Cancer Res 53: 826-832, 1993.
247. Kohn EC and Liotta LA: L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82: 54-60, 1990.
248. Kohn EC, Sandeen MA and Liotta LA: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52: 3208-3212, 1992.
249. Kreuter MH, Leake RE, Rinaldi F, Muller KW, Maidhof A, Muller WE and Schroder HC: Inhibition of intrinsic protein tyrosine kinase activity of EGF receptor kinase complex from human breast cancer cells by the marine sponge metabolites (+)-aeroplysinin-1. Comp Biochem Physiol 97: 151-158, 1990.
250. Chun JS and Jacobson BS: Spreading of HeLa cells on a collagen substratum requires a second messenger formed by the lipoxygenase metablism of arachidonic acid released by collagen receptor clustering. Mol Biol Cell 3: 481-492, 1992.
251. Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tonooka S, Samukawa K and Azuma I: Inhibitory effect o tumor-metastasis in mice by saponins, ginsenoside-Rb2, 20(r)-ginsenoside-Rg3 and 20(s)-ginsenoside-Rg3, of red ginseng. Biol Pharmacol Bull 18: 1197-1202, 1995.
252. Liu L, Hudgins WR, Shack S, Yin MQ and Samid D: Cinnamic acid - a natural product with potential use in cancer. Int J Cancer 62: 345-350, 1995.
253. Han JH, Law SW, Keller PM, Kniskern PJ, Silberklang M, Tung JS, Gasic TB, Gasic GJ, Friedman PA and Ellis RW: Cloning and expression of cDNA encoding antistasin, a leech-derived protein having anticoagulant and anti-metastatic properties. Gene 75: 4757, 1989.
254. Brankamp RG, Manley GD, Owen TJ, Krstenansky JL and Cardin AD: Specific inhibition of binding of antistasin and [A103,106,108] antistasin 93-119 to sulfatide (Gal(3- SO4)β 1-1Cer) by glycosaminoglycans. FEBS Lett 296: 145-147, 1992.
255. Brankamp RG, Blankenship DT, Sunkara PS and Cardin AD: Ghilantens: anticoagulant-antimetastatic proteins from the South American leech, Haementeria ghilianii. J Lab Clin Med 115: 89-97, 1990.
256. Cha HJ, Bae SK, Lee HY, Sato H, Seiki M, Park BC and Kim KW: Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 56: 2281-2284, 1996.
257. Lee HY, Chung HY, Kim KH, Lee JJ and Kim KW: Induction of differentiation in the cultured F9 teratocarcinoma stem cells by trierpene acids. J Cancer Res Clin Oncol 120: 513-518, 1994.
258. Tokuda H, Ohigashi H, Koshimizu H and Ito Y: Inhibitory effects of ursolic and oleanolic acid on skin tumor promotion by 12-tetradecanoylphorbol-13 acetate. Cancer Lett 33: 279-285, 1986.
259. Ohihashi H, Takamura H, Koshimizu H, Tokuda H and Ito Y: Search for possible antitumor promoters by inhibition of 12-o-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus activation, ursolic and oleanolic acid from an antiinflammatory Chinese medical plant, Glechoma hederacear L. Cancer Lett 30: 143-151, 1986.
260. Sohn KH, Lee HY, Chung HY, Young HS, Yi SY and Kim KW: Anti-angiogenic activity of triterpene acids. Cancer Lett 94: 213-218, 1995.
261. Yoon TJ, Yoo YC, Choi OB, Do MS, Kang TB, Lee SW, Azuma I and Kim JB: Inhibitory effect of Korean mistletoe (viscum-album coloratum) extract on tumor angiogenesis and metastasis of hematogenous and non-hematogenous tumor-cells in mice. Cancer Lett 97: 83-91, 1995.
262. Schirner M and Schneider MR: The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 118: 497-501, 1992.
263. Schirner M and Schneider MR: Rodent model of systemic mammary-tumor disease by surgical removal of the spontaneously metastasizing SMT2A mammary-carcinoma - inhibitory effect of the stable prostacyclin analog cicaprost on occult metastasis. Int J Cancer 62: 205-209, 1995.
264. Schneider MR, Schillinger E, Schirner M, Skuballa W, Sturzebecher S and Witt W: Effects of prostacyclin analogues in in vivo tumor models. Adv Prostaglandin Thromboxane Leukotriene Res 21B: 901-908, 1991.
265. Schwalke MA, Tzanakakis GN and Vezeridis MP: Effects of prostacyclin on hepatic metastases from human pancreatic cancer in the nude mouse. J Surg Res 49: 164-167, 1990.
266. Schallier DC, Bruyneel EA, Storme GA, Hilgard P and Mareel MM: Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res 11: 1285-1292, 1991.
267. Reich R and Martin GR: Identification of arachidonic-acid pathways required for the invasive and metastatic activity of malignant-tumor cells. Prostaglandins 51: 1-17, 1996.
268. Lapierre F, Holme K, Lam L, Tressler RJ, Storm N, Wee J, Stack RJ, Castellot J and Tyrrell DJ: Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, antitumor and antimetastatic properties. Glycobiology 6: 355-366, 1996.
269. Ishikawa T, Ura M, Yamamoto T, Tanaka Y and Ishitsuka H: Selective-inhibition of spontaneous pulmonary metastasis of Lewis lung-carcinoma by 5′-deoxy-5 fluorouridine. Int J Cancer 61: 516-521, 1995.
270. Konno Y, Takahashi S, Naruse R, Mikami T, Matsumoto T, Suzuki S and Suzuki M: Antimetastatic effect of yeast mannanbleomycin conjugate against mouse Lewis lung-carcinoma. Biol Pharmacol Bull 17: 748-752, 1994.
271. Repesh LA, Drake SR, Warner MC, Downing SW, Jyring R, Seftor EA, Hendrix MJ and McCarthy JB: Adriamycin-induced inhibition of melanoma cell invasion is correlated with decreases in tumor cell motility and increases in focal contact formation. Clin Exp Metastasis 11: 91-102, 1993.
272. Kobayashi H, Matsunaga K and Oguchi Y: Antimetastatic effects of PSK (krestin), a protein-bound polysaccharide obtained from basidiomycetes. Cancer Epidemiol Biomarker Prevent 4: 275-281, 1995.
273. Woynarowska B, Skrincosky DM, Haag A, Sharma M, Matta K and Bernacki RJ: Inhibition of lectin mediated ovarian tumor-cell adhesion by sugar analogs. J Biol Chem 269: 22797-22803, 1994.
274. Fazely F, Ledinko N and Smith DJ: Inhibition by retinoids of in vitro invasive ability of human lung carcinoma cells. Anticancer Res 8: 1387-1392, 1988.
275. MacGarvey TW and Persky B: The effects of retinoic acid and butyric acid on in vitro migration by murine B16a cells. Scan Microsc 3: 591-604, 1989.
276. Couch MJ, Pauli BU, Weinstein RS and Coon JS: Modulation of the metastatic phenotype by 13-cis-retinoic acid. J Natl Cancer Inst 78: 971-977, 1987.
277. Edward M and MacKie RM: Modulation of melanoma cell adhesion to basement membrane components by retinoic acid. J Cell Biol 93: 155-161, 1989.
278. Lotan R, Amos B, Watanabe H and Raz A: Suppression of melanoma cell motility factor receptor expression by retinoic acid. Cancer Res 52: 4878-4884, 1992.
279. Kono T, Furukawa M, Tanii T, Taniguchi S, Mizuno N, Ishii M and Hamada T: Effect of retinoic acid on the infiltration of murine melanoma cells into the type I collagen gel. Acta Derm Venereol 71: 41-44, 1991.
280. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA and Nicolson GL: Suramin, a potent inhibitor of melanoma heparanase and invasion. J Biol Chem 266: 9661-9666, 1991.
281. Behrendt N, Ronne E and Dano K: Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 268: 5985-5989, 1993.
282. Zabrenetzky VS, Kohn EC and Roberts DD: Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res 50: 5937-5942, 1990.
283. Van Oosterom AT, DeSmedt EA and Dennis LJ: Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease. Eur J Cancer 26: 422, 1990.
284. Marcel MH, Storme GA and Dragonetti CH: Antiinvasive activity of estramustine on malignant MO4 mouse cells and DU145 human prostate carcinoma cell in vitro. Cancer Res 48: 1842-1849, 1988.
285. Pienta KJ, Isaacs WB, Vindivich D and Coffey DS: The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145: 199-202, 1991.
286. Seftor RE, Seftor EA, Grimes WJ, Liotta LA, Stetler-Stevenson WG, Welch DR and Hendrix MJ: Human melanoma cell invasion is inhibited in vitro by swainsonine and deoxymannojirimycin with a concomitant decrease in collagenase IV expression. Melanoma Res 1: 43-54, 1991.
287. Spearman MA, Ballon BC, Gerrard JM, Greenberg AH and Wright JA: The inhibition of platelet aggregation of metastatic H-ras-transformed 10T1/2 fibroblasts with castanospermine, an N-linked glycoprotein processing inhibitor. Cancer Lett 60: 185-191, 1991.
288. Galustian C and Guillou PJ: Mechanisms of inhibition of tumour cell invasion by swainsonine, a glycoprotein processing inhibitor. Br J Surg 81: 757, 1994.
289. Newton SA, White SL, Humphries MJ and Olden K: Swainsonine inhibition of spontaneous metastasis. J Natl Cancer Inst 81: 1024-1028, 1989.
290. Dennis JW, White SL, Freer AM and Dime D: Carbonoyloxy analogs of the antimetastatic drug swainsonine - activation in tumor-cells by esterases. Biochem Pharmacol 46: 1459-1466, 1993.
291. Leto G, Tumminello FM, Gebbia N, Woynarowska B and Bernacki RJ: Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice. Anticancer Res 10: 265-269, 1990.